Literature DB >> 18777015

Physicochemical properties, pharmacokinetics, and pharmacodynamics of intravenous hematin: a literature review.

Scott W K Siegert1, Robert J Holt.   

Abstract

INTRODUCTION: Intravenous (i.v.) hematin has been used in the treatment of acute intermittent porphyria (AIP) since the early 1970s and commercially available as Panhematin (hemin for injection; Ovation Pharmaceuticals, Inc., USA) since 1983, yet no publication to date has attempted to summarize the known pharmacodynamics and toxicological actions of hematin and the implications on treatment. It is the objective of this literature review to identify, consolidate, and summarize the available scientific literature regarding the physicochemical properties, pharmacokinetics, toxicology, and hemostatic effects of i.v. hematin injections.
METHODS: A comprehensive search of the available literature was performed and resulting data were summarized. Furthermore, previously unpublished toxicology data extracted from the original New Drug Application were included.
RESULTS: Hematin, reconstituted with sterile water, rapidly degrades and it is hypothesized that the degradation products lead to morbidities such as thrombophlebitis, thrombocytopenia, and transient anticoagulation. Reconstitution with human serum albumin produces a well-tolerated hematin preparation and improves its stability significantly. The clearance of i.v. hematin infusions are shown to fit a two-compartment model consisting of a rapid initial rate followed by a slower and prolonged second phase. This model is supported by the evidence demonstrating that hematin is first bound by hemopexin and, upon saturation, second by albumin. The highest i.v. human hematin dose reported in the literature was 12.2 mg/kg (1000 mg) and resulted in acute gastrointestinal pain, paresthesia, and acute tubercular necrosis. The patient's renal function returned to normal over the following 15 hours.
CONCLUSION: Hematin, at doses approved by the US Food and Drug Administration, is generally well tolerated. Reconstitution with albumin produces a significantly more stable preparation than reconstitution with sterile water and may lead to a more tolerable administration with less hemostatic interference. Hematin, once administered, is cleared hepatically and is best represented pharmacokinetically by a two-compartment model comprised of a rapid initial phase followed by a slower second phase.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18777015     DOI: 10.1007/s12325-008-0094-y

Source DB:  PubMed          Journal:  Adv Ther        ISSN: 0741-238X            Impact factor:   3.845


  15 in total

1.  Targeting heme oxygenase after intracerebral hemorrhage.

Authors:  Jing Chen-Roetling; Xiangping Lu; Raymond F Regan
Journal:  Ther Targets Neurol Dis       Date:  2015-01-03

2.  Disease pharmacokinetic-pharmacodynamic modelling in acute intermittent porphyria to support the development of mRNA-based therapies.

Authors:  Zinnia P Parra-Guillen; Antonio Fontanellas; Lei Jiang; Daniel Jericó; Paolo Martini; Diego Vera-Yunca; Marjie Hard; Lin T Guey; Iñaki F Troconiz
Journal:  Br J Pharmacol       Date:  2020-04-14       Impact factor: 8.739

3.  Hemin activation of innate cellular response blocks human immunodeficiency virus type-1-induced osteoclastogenesis.

Authors:  Kazuyo Takeda; Rewati Adhikari; Kenneth M Yamada; Subhash Dhawan
Journal:  Biochem Biophys Res Commun       Date:  2015-05-19       Impact factor: 3.575

4.  Nrf2-dependent induction of innate host defense via heme oxygenase-1 inhibits Zika virus replication.

Authors:  Hanxia Huang; Barry Falgout; Kazuyo Takeda; Kenneth M Yamada; Subhash Dhawan
Journal:  Virology       Date:  2017-01-06       Impact factor: 3.616

5.  Hemin causes mitochondrial dysfunction in endothelial cells through promoting lipid peroxidation: the protective role of autophagy.

Authors:  Ashlee N Higdon; Gloria A Benavides; Balu K Chacko; Xiaosen Ouyang; Michelle S Johnson; Aimee Landar; Jianhua Zhang; Victor M Darley-Usmar
Journal:  Am J Physiol Heart Circ Physiol       Date:  2012-01-13       Impact factor: 4.733

6.  Tissue heme oxygenase-1 exerts anti-inflammatory effects on LPS-induced pulmonary inflammation.

Authors:  F M Konrad; U Knausberg; R Höne; K-C Ngamsri; J Reutershan
Journal:  Mucosal Immunol       Date:  2015-05-06       Impact factor: 7.313

7.  Heme oxygenase-1 is induced in peripheral blood mononuclear cells of patients with acute pancreatitis: a potential therapeutic target.

Authors:  Aida Habtezion; Raymond Kwan; Alice L Yang; Maureen E Morgan; Ehsaan Akhtar; Stephen P Wanaski; Stephen D Collins; Eugene C Butcher; Ahmad Kamal; M Bishr Omary
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2010-10-21       Impact factor: 4.052

8.  Panhematin provides a therapeutic benefit in experimental pancreatitis.

Authors:  Aida Habtezion; Raymond Kwan; Ehsaan Akhtar; Stephen P Wanaski; Stephen D Collins; Ronald J Wong; David K Stevenson; Eugene C Butcher; M Bishr Omary
Journal:  Gut       Date:  2010-12-15       Impact factor: 23.059

9.  Therapeutic potential of the heme oxygenase-1 inducer hemin against Ebola virus infection.

Authors:  Hanxia Huang; Krishnamurthy Konduru; Veronica Solovena; Zhao-Hua Zhou; Namita Kumari; Kazuyo Takeda; Sergei Nekhai; Sina Bavari; Gerardo G Kaplan; Kenneth M Yamada; Subhash Dhawan
Journal:  Curr Trends Immunol       Date:  2016

10.  First-in-human study demonstrating pharmacological activation of heme oxygenase-1 in humans.

Authors:  A E Bharucha; A Kulkarni; K M Choi; M Camilleri; M Lempke; G J Brunn; S J Gibbons; A R Zinsmeister; G Farrugia
Journal:  Clin Pharmacol Ther       Date:  2009-12-02       Impact factor: 6.875

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.